• Trichostatin A: Mechanisms, Evidence and Research Limits

  2026-10-08

  Trichostatin A (TSA) is a widely used broad-acting HDAC inhibitor in epigenetic and cancer research. This overview separates established compound biology from supplier-reported claims and examines how recent findings on HDAC6-dependent α-tubulin lactylation complicate simple interpretations of HDAC inhibition. It covers conceptual applications in epigenetic regulation in cancer, neuronal biology and cytoskeletal research, while emphasizing evidence strength, model limitations, target selectivity and the boundaries of translating cell-culture findings into therapeutic conclusions.

• Anlotinib and VEGFR2-Targeted Tumor Angiogenesis

  2026-10-08

  The reference study characterizes anlotinib as a highly potent, selective VEGFR2 tyrosine kinase inhibitor that suppresses angiogenic signaling, endothelial responses, and tumor-associated vascular growth in preclinical models. Its strongest contribution is the alignment of molecular selectivity with cellular, ex vivo, and in vivo evidence, while the study also shows why anti-angiogenic activity should not be equated with direct tumor-cell cytotoxicity.

• Digoxin, HIF-1α, and Thyroid Eye Disease

  2026-10-07

  A 2026 Biochemical and Biophysical Research Communications pre-proof identifies HIF-1α as a mechanistic link between hypoxia, inflammation, fibrosis, STAT3 signaling, and GSDME-associated pyroptosis in thyroid eye disease. The study further reports that Digoxin reverses these cellular responses, supporting its use as a pharmacological probe and possible repurposing candidate, while leaving important questions about specificity, safety, and clinical translation unresolved.

• Amikacin Sulfate: Evidence Across Scales

  2026-10-07

  Amikacin Sulfate is best understood by separating ribosomal activity, intracellular exposure, tissue distribution, and translational evidence. This article develops an evidence-centered framework and uses the 2024 KR-12 review to clarify what antimicrobial delivery claims can—and cannot—demonstrate.

• Puerarin, Gut Microbiota, and Adipose Thermogenesis

  2026-10-06

  A 2026 Phytotherapy Research study examined how puerarin affects glucose and lipid metabolism in diabetic mice through coordinated changes in gut microbiota, fecal metabolites, adipose thermogenesis, and insulin-related signaling. Its main contribution is an integrated gut–adipose framework, although the findings remain preclinical and do not establish clinical efficacy or definitive causal relationships in humans.

• Probenecid: MRP Inhibition and Evidence Limits

  2026-10-06

  Probenecid, also called 4-(dipropylsulfamoyl)benzoic acid, is described as an organic anion transporter, MRP, and pannexin-1 modulator. Vendor-reported findings support research interest in multidrug resistance reversal in leukemia and neuroprotection in cerebral ischemia/reperfusion injury, but the supplied CD8+ T-cell study does not test probenecid and should not be treated as direct evidence for its activity.

• Nilotinib (AMN-107) and Translational Stress

  2026-10-05

  Nilotinib (AMN-107) provides a precise pharmacological anchor for studying BCR-ABL, KIT, and PDGFR signaling without assuming that every downstream phenotype is kinase-direct. This analysis connects that framework with new evidence on GCN2, eIF2α, and ZAKα-mediated translational control while clearly separating established findings from testable interpretation.

• IRF1–NLRC5 Drives Macrophage PANoptosis in Lung IRI

  2026-10-05

  A 2026 study identifies an extracellular histone–mitochondria–IRF1–NLRC5 pathway linking lung ischemia–reperfusion injury with macrophage PANoptosis. Its mouse, cellular, and patient-sample evidence supports a mechanistic model in which oxidized mitochondrial DNA promotes inflammatory cell death, while also highlighting the need for further causal and translational validation.

• 2',7'-Dichlorofluorescein Diacetate: Reading ROS Signals

  2026-10-04

  2',7'-Dichlorofluorescein diacetate is a widely used fluorescent ROS probe, but its signal is best understood as an integrated redox response rather than a selective molecular measurement. This article examines how to interpret the probe alongside evidence from ROS-responsive pancreatic cancer nanocarriers.

• DOT1L Inhibition and Innate Immunity in Myeloma

  2026-10-03

  A 2025 Cancer Letters study links DOT1L dependency in multiple myeloma to DNA damage-associated STING signaling, interferon-response genes, and suppression of IRF4–MYC activity. The findings support DOT1L inhibition as a potential way to reprogram tumor-cell innate immune signaling and improve responses to lenalidomide, while remaining primarily preclinical.

• Engineering the Cas9 mRNA Translation Window

  2026-10-01

  A translational framework for evaluating capped, m1Ψ-modified Cas9 mRNA across CRISPR-Cas9 genome editing workflows, with practical guidance on validation, delivery, reproducibility, and strategic product selection.

• Oligo (dT) 25 Beads for mRNA Workflows

  2026-10-01

  Use Oligo (dT) 25 Beads to enrich intact, polyadenylated eukaryotic mRNA from total RNA, cells, or tissues before cDNA synthesis, RT-PCR, and sequencing. This guide connects magnetic capture with practical assay design, including how to study the NSD1–PPARγ–PTEN axis without confusing transcript abundance with protein methylation.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-10-01

  The reference paper reviews dabigatran etexilate as the first marketed oral direct thrombin inhibitor, emphasizing its prodrug activation, predictable anticoagulant activity, clinical efficacy, and renal considerations. Its practical significance lies in addressing limitations of vitamin K antagonists and parenteral anticoagulants while clarifying bleeding, gastrointestinal, and patient-selection issues.

• SEC-seq Links VEGF-A Secretion to MSC States

  2026-09-30

  The reference study introduces secretion encoded single-cell sequencing (SEC-seq), a nanovial-based method that pairs secreted VEGF-A measurements with transcriptomic profiles from individual mesenchymal stromal cells. Its central finding is that VEGF-A release varies substantially between cells and is only weakly predicted by VEGFA transcript abundance, while highly secreting cells share a distinct gene-expression state across normoxic and hypoxic conditions.

• CCG-1423 for Reproducible Cell Assays

  2026-09-29

  Learn how CCG-1423 (SKU B4897) can support mechanistic cell viability, proliferation, invasion, and apoptosis studies involving RhoA transcriptional signaling. This scenario-based guide covers assay design, DMSO compatibility, storage, interpretation, and practical product selection using documented specifications and current pathway literature.

7993 records 1/533 page Next 12345 下5页 Last page